









Mercado
/
Acciones
/
nasdaq-cdna
/

CareDx Inc

CDNA

19.470USD

+1.120+6.10%

Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min

1.00BCap. mercado

14.43P/E TTM



CareDx Inc

19.470

+1.120+6.10%

Descripción general Finanzas Análisis Compañía

Descripción general

Finanzas

Análisis

Compañía

Más Datos de CareDx Inc Compañía

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.

Información de CareDx Inc



Símbolo de cotizaciónCDNA

Nombre de la empresaCareDx Inc

Fecha de salida a bolsaJul 17, 2014

Director ejecutivoHanna (John W)

Número de empleados644

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 17

Dirección8000 Marina Blvd

CiudadBRISBANE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal94005

Teléfono14152872300

Sitio Webhttps://www.caredx.com/

Símbolo de cotizaciónCDNA

Fecha de salida a bolsaJul 17, 2014

Director ejecutivoHanna (John W)

Ejecutivos de CareDx Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Peter Maag, Ph.D.

Independent Director

298.28K

-10000.00%

Ms. Jessica Meng

Chief Commercial Officer

176.78K

+67149.00%

Mr. Michael D. Goldberg

Independent Chairman of the Board

146.89K

+1492.00%

Dr. Frederick E. (Fred) Cohen, M.D.

Independent Director

144.69K

+12103.00%

Mr. Nathan Smith

Chief Financial Officer

79.02K

+37016.00%

Mr. William A. (Bill) Hagstrom

Independent Director

43.41K

Ms. Christine M. Cournoyer

Independent Director

38.58K

+12103.00%

Mr. Jeffrey Adam Novack

General Counsel, Secretary

37.63K

+27439.00%

Mr. Suresh Gunasekaran

Director

27.45K

+27453.00%

Mr. George W. Bickerstaff, III

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Peter Maag, Ph.D.

Independent Director

298.28K

-10000.00%

Ms. Jessica Meng

Chief Commercial Officer

176.78K

+67149.00%

Mr. Michael D. Goldberg

Independent Chairman of the Board

146.89K

+1492.00%

Dr. Frederick E. (Fred) Cohen, M.D.

Independent Director

144.69K

+12103.00%

Mr. Nathan Smith

Chief Financial Officer

79.02K

+37016.00%

Mr. William A. (Bill) Hagstrom

Independent Director

43.41K

Desglose de ingresos

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Testing Service revenue

72.17M

0.00%

Digital and other revenue

15.41M

0.00%

Product revenue

12.48M

0.00%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

95.06M

0.00%

Rest of the world

5.00M

0.00%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Testing Service revenue

72.17M

0.00%

Digital and other revenue

15.41M

0.00%

Product revenue

12.48M

0.00%

Estadísticas de accionistas

Actualizado: lun., 17 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

8.01%

The Vanguard Group, Inc.

6.64%

Baron Capital Management, Inc.

6.13%

State Street Investment Management (US)

4.99%

Ophir Asset Management Pty Ltd

4.27%

Otro

69.95%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

8.01%

The Vanguard Group, Inc.

6.64%

Baron Capital Management, Inc.

6.13%

State Street Investment Management (US)

4.99%

Ophir Asset Management Pty Ltd

4.27%

Otro

69.95%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

41.70%

Investment Advisor

35.07%

Hedge Fund

21.15%

Individual Investor

4.50%

Research Firm

3.27%

Pension Fund

0.56%

Bank and Trust

0.41%

Insurance Company

0.03%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

443

52.64M

115.22%

+43.46K

2025Q3

457

52.61M

115.96%

-1.80M

2025Q2

454

53.72M

112.39%

-1.85M

2025Q1

443

55.89M

106.19%

-3.01M

2024Q4

439

52.97M

108.30%

+1.05M

2024Q3

434

51.58M

120.50%

-825.62K

2024Q2

407

52.51M

127.45%

-1.22M

2024Q1

435

53.86M

132.45%

-14.73M

2023Q4

448

52.78M

128.80%

-2.04M

2023Q3

476

54.42M

142.26%

-1.69M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

4.12M

8.01%

+53.87K

+1.33%

Sep 30, 2025

The Vanguard Group, Inc.

3.74M

7.27%

-1.16M

-23.69%

Sep 30, 2025

Baron Capital Management, Inc.

3.16M

6.13%

+719.52K

+29.54%

Sep 30, 2025

State Street Investment Management (US)

2.57M

4.99%

+386.30K

+17.72%

Sep 30, 2025

Ophir Asset Management Pty Ltd

2.20M

4.27%

+304.95K

+16.11%

Sep 30, 2025

Deerfield Management Company, L.P.

2.19M

4.26%

+2.19M

Sep 30, 2025

Braidwell LP

2.18M

4.24%

+2.18M

Sep 30, 2025

ARK Investment Management LLC

2.17M

4.22%

+70.47K

+3.36%

Sep 30, 2025

Gagnon Securities LLC

1.73M

3.36%

-404.70K

-18.96%

Sep 30, 2025

Amova Asset Management Co., Ltd.

1.74M

3.38%

+503.14K

+40.68%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

ARK Genomic Revolution ETF

2.89%

ROBO Global Healthcare Technology & Innovation ETF

1.93%

Global X Genomics & Biotechnology ETF

0.87%

Franklin Genomic Advancements ETF

0.72%

State Street SPDR S&P Biotech ETF

0.34%

Direxion Daily S&P Biotech Bull 3X Shares

0.21%

iShares Micro-Cap ETF

0.16%

Fidelity Enhanced Small Cap ETF

0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.11%

Principal U.S. Small-Cap ETF

0.1%

ARK Genomic Revolution ETF

Proporción2.89%

ROBO Global Healthcare Technology & Innovation ETF

Proporción1.93%

Global X Genomics & Biotechnology ETF

Proporción0.87%

Franklin Genomic Advancements ETF

Proporción0.72%

State Street SPDR S&P Biotech ETF

Proporción0.34%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.21%

iShares Micro-Cap ETF

Proporción0.16%

Fidelity Enhanced Small Cap ETF

Proporción0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proporción0.11%

Principal U.S. Small-Cap ETF

Proporción0.1%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

